Table 1.
No. | Peptide | Sequence | IC50 (μM) |
||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Vif25-39 | V | K | H | H | M | Y | V | S | G | K | A | R | G | W | F | 0.6 |
2 | Vif 25-39 (27AA28) | V | K | A | A | M | Y | V | S | G | K | A | R | G | W | F | 4.5 |
3 | Vif 25-39 (26A) | V | A | H | H | M | Y | V | S | G | K | A | R | G | W | F | 8 |
4 | Vif 25-39 (26AAA28) | V | A | A | A | M | Y | V | S | G | K | A | R | G | W | F | 10 |
5 | Vif25-36 | V | K | H | H | M | Y | V | S | G | K | A | R | 50 | |||
6 | Vif25-34 | V | K | H | H | M | Y | V | S | G | K | NI* | |||||
7 | Vif26-39 | K | H | H | M | Y | V | S | G | K | A | R | G | W | F | 80 | |
8 | Vif30-39 | Y | V | S | G | K | A | R | G | W | F | NI | |||||
9 | A3F224-231 | VV | K | H | H | S | P | V | NI | ||||||||
| |||||||||||||||||
10 | Vif105-119 | Q | L | I | H | L | Y | Y | F | D | C | F | S | E | S | A | 0.1 |
11 | Vif107-115 | I | H | L | Y | Y | F | D | C | F | 0.1 | ||||||
12 | Vif107-115(110AA111) | I | H | L | A | A | F | D | C | F | NI | ||||||
13 | Vif107-115(112A) | I | H | L | Y | Y | A | D | C | F | NI | ||||||
14 | Vif109-117 | L | Y | Y | F | D | C | F | S | E | NI | ||||||
15 | Vif109-115 | L | Y | Y | F | D | C | F | NI | ||||||||
16 | Vif 107-113 | I | H | L | Y | Y | F | D | 110 | ||||||||
17 | A3F304-312 | A | R | L | Y | Y | F | W | D | T | 8 | ||||||
18 | A3F305-311 | R | L | Y | Y | F | W | D | 1 | ||||||||
19 | Vif107-115 (Reverse) | F | C | D | F | Y | Y | L | H | I | NI | ||||||
20 | Vif107-115(scrambled) | I | C | F | L | H | Y | D | F | Y | NI | ||||||
| |||||||||||||||||
21 | A3G293-307 | Q | E | M | A | K | F | I | S | K | N | K | H | V | S | L | NI |
22 | A3G226-240 | R | M | H | N | D | T | W | V | L | L | N | Q | R | R | G | 60 |
23 | A3G226-231 | R | M | H | N | D | T | NI | |||||||||
24 | A3G211-225 | W | V | R | G | R | H | E | T | Y | L | C | Y | E | V | E | 10 |
denotes No Inhibition.